Evidence map›Paper›PMID 31376591›Full record

ArticleJournal of chromatography. B, Analytical technologies in the biomedical and life sciences2019

Measurement of the DNA alkylating agents busulfan and melphalan in human plasma by mass spectrometry.

Ryan C Schofield, Heather J Landau, Sergio A Giralt, Gunjan L Shah, Michael Scordo, Andrew Lin, Elaine Zanutto, Lakshmi V Ramanathan, Melissa S Pessin, Dean C Carlow

Open access · greenAbstract readEvaluation Study
In one paragraph

Article in Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 12 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Ryan C SchofieldDepartment of Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States.
Heather J LandauAdult Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY, United States.
Sergio A GiraltAdult Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY, United States.
Gunjan L ShahAdult Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY, United States.
Michael ScordoAdult Bone Marrow Transplant Service, Memorial Sloan Kettering Cancer Center, Weill Cornell Medical College, New York, NY, United States.
Andrew LinDepartment of Pharmacy, Memorial Sloan Kettering Cancer Center, New York, NY, United States.
Elaine ZanuttoStatistics Department, The Wharton School, University of Pennsylvania, Philadelphia, PA, United States.
Lakshmi V RamanathanDepartment of Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States.
Melissa S PessinDepartment of Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States.
Dean C CarlowDepartment of Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States. Electronic address: carlowd@mskcc.org.
Memorial Sloan Kettering Cancer Center · USCornell University · USUniversity of Pennsylvania · US

Funding

X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Nicholas D Socci · 1985 to 2026
$347.4M
NCI NIH HHS P30 CA008748
6 · The paper itself

Abstract

Busulfan and melphalan are cytotoxic DNA alkylating agents that are used in many hematopoietic stem cell transplantation (HCT) conditioning regimens. We report the development of an assay using turbulent flow liquid chromatography (TFLC) and tandem mass spectrometry to simultaneously measure the concentration of busulfan (Bu) and melphalan (Mel) in human plasma. The method involves precipitating proteins in the plasma specimen with an organic solvent containing deuterated internal standards of both compounds. Following centrifugation, an aliquot of the supernatant was injected into the TFLC mass spectrometry system operated in the positive ion mode. The analytical measurement range for both compounds was 10-5000 ng/mL, and with validated dilutions the reportable range was extended to 25,000 ng/mL. Intra-day and inter-day (n = 20 day) precision studies showed a coefficient of variation (CV) of <7% at several concentrations across the measurement range. To determine accuracy recovery studies were performed at several concentrations spanning the measurement range. Recoveries for both compounds were between 98 and 103%. Additionally, busulfan was compared with an existing assay and showed excellent correlation. Experiments were conducted to rule out matrix effects, carryover and interference from endogenous substances. The validated clinically reportable range (CRR) and assay precision will allow this assay to be used clinically to monitor and adjust Mel and Bu levels to ensure better therapeutic outcomes and also to support clinical trials aimed at better defining therapeutic ranges.

Indexed as

Alkylating AgentsBusulfanChromatography, High Pressure LiquidDNAHumansImmunosuppressive AgentsMelphalanTandem Mass SpectrometryAlkylating AgentsBusulfanDNAImmunosuppressive AgentsMelphalanBusulfanMelphalanPharmacokinetic studiesTandem mass spectrometryTurbulent flow liquid chromatography

Identifiers

PMID31376591
PMCPMC6692901
OpenAlexW2953987804

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.